BACKGROUND: Infection with high-risk human papillomavirus is an important factor associated with cervical cancer, and the distribution of HPV types varies greatly worldwide. Determination of type-specific HPV prevalence constitutes an important step towards the development of vaccines for the prevention of cervical cancer. METHODS: The human papillomavirus (HPV) genotypes in 190 cervical cancer specimens taken from the Sichuan province, the most populous province of Southwest China, were detected by a combination of MY09/11 consensus primers PCR (MY09/11 PCR), type-specific primers one-step PCR (One-step TS PCR) and E6/E7 gene type-specific primers nested PCR (Nested TS PCR). The prevalence and distribution of HPV in patients with cervical cancer, especially for HPV types 16, 18, 52, 58 and 59, suspected to be most common in certain parts of China, was investigated. RESULTS: The HPV infection rates detected by MY09/11 PCR, One-step TS PCR and Nested TS PCR were 159 (83.7%), 145 (76.3%) and 172 (90.5%), respectively. The overall HPV prevalence was 93.2% (177/190). The positive specimens for HPV16, 18, 52, 58 and 59 detected by One-step TS-PCR were 111 (58.4%), 14 (7.4%), 6 (3.2%), 13 (6.8%) and 4 (2.1%), respectively. By Nested TS-PCR analysis, the detection rates of HPV16, 52, 58 and 59 were increased to 140 (73.7%), 30 (15.8%), 37 (19.5%) and 25 (13.2%), while only 4 (2.1%) additional specimens were found to be infected with HPV18. CONCLUSION: Our data demonstrate that, besides HPV 16, which was found to be the most prevalent type, HPV types 58, 52 and 59 are more prevalent than HPV18 in women with cervical cancer in the Sichuan area of China.
BACKGROUND: Infection with high-risk human papillomavirus is an important factor associated with cervical cancer, and the distribution of HPV types varies greatly worldwide. Determination of type-specific HPV prevalence constitutes an important step towards the development of vaccines for the prevention of cervical cancer. METHODS: The human papillomavirus (HPV) genotypes in 190 cervical cancer specimens taken from the Sichuan province, the most populous province of Southwest China, were detected by a combination of MY09/11 consensus primers PCR (MY09/11 PCR), type-specific primers one-step PCR (One-step TS PCR) and E6/E7 gene type-specific primers nested PCR (Nested TS PCR). The prevalence and distribution of HPV in patients with cervical cancer, especially for HPV types 16, 18, 52, 58 and 59, suspected to be most common in certain parts of China, was investigated. RESULTS: The HPV infection rates detected by MY09/11 PCR, One-step TS PCR and Nested TS PCR were 159 (83.7%), 145 (76.3%) and 172 (90.5%), respectively. The overall HPV prevalence was 93.2% (177/190). The positive specimens for HPV16, 18, 52, 58 and 59 detected by One-step TS-PCR were 111 (58.4%), 14 (7.4%), 6 (3.2%), 13 (6.8%) and 4 (2.1%), respectively. By Nested TS-PCR analysis, the detection rates of HPV16, 52, 58 and 59 were increased to 140 (73.7%), 30 (15.8%), 37 (19.5%) and 25 (13.2%), while only 4 (2.1%) additional specimens were found to be infected with HPV18. CONCLUSION: Our data demonstrate that, besides HPV 16, which was found to be the most prevalent type, HPV types 58, 52 and 59 are more prevalent than HPV18 in women with cervical cancer in the Sichuan area of China.
Authors: Andrea L Fuessel Haws; Qin He; Peter L Rady; Lifang Zhang; James Grady; Thomas K Hughes; Kendra Stisser; Rolf Konig; Stephen K Tyring Journal: J Virol Methods Date: 2004-12-01 Impact factor: 2.014
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: K Sotlar; D Diemer; A Dethleffs; Y Hack; A Stubner; N Vollmer; S Menton; M Menton; K Dietz; D Wallwiener; R Kandolf; B Bültmann Journal: J Clin Microbiol Date: 2004-07 Impact factor: 5.948
Authors: Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen Journal: Virology Date: 2004-06-20 Impact factor: 3.616
Authors: Keith W K Lo; Y F Wong; May K M Chan; James C B Li; J S Poon; Vivian W Wang; S N Zhu; T M Zhang; Z G He; Q L Wu; G D Li; John S L Tam; T Kahn; P Lam; T H Cheung; Tony K H Chung Journal: Int J Cancer Date: 2002-07-20 Impact factor: 7.396
Authors: G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney Journal: J Natl Cancer Inst Date: 1995-09-20 Impact factor: 13.506
Authors: F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah Journal: J Natl Cancer Inst Date: 1995-06-07 Impact factor: 13.506
Authors: Stephanie Si Liu; Kelvin Yuen Kwong Chan; Rebecca Ching Yu Leung; Karen Kar Loen Chan; Kar Fai Tam; May Hiu Mei Luk; Sue Seen Tsing Lo; Daniel Yee Tak Fong; Annie Nga Yin Cheung; Zhong Qiu Lin; Hextan Yuen Sheung Ngan Journal: PLoS One Date: 2011-05-03 Impact factor: 3.240
Authors: Andrea Molina-Pineda; María Guadalupe López-Cardona; Laura Patricia Limón-Toledo; Juan Carlos Cantón-Romero; María Guadalupe Martínez-Silva; Holanda Vanesa Ramos-Sánchez; María Guadalupe Flores-Miramontes; Pedro de la Mata-González; Luis F Jave-Suárez; Adriana Aguilar-Lemarroy Journal: BMC Infect Dis Date: 2020-11-25 Impact factor: 3.090
Authors: Paul K S Chan; María Alejandra Picconi; Tak Hong Cheung; Lucia Giovannelli; Jong Sup Park Journal: Crit Rev Clin Lab Sci Date: 2012 Jul-Aug Impact factor: 6.250